Henderson in partnership talks

Companies: HML

16/03/2006

Drug discovery minnow Henderson Morley is negotiating a possible licensing deal for its Ionic Contra Viral Therapy (ICVT) technology.

AIM-quoted Henderson, which lost £383,000 in the six months to October, originally developed ICVT as a treatment for herpes. More recently, the company broadened its potential applications to include skin warts, verrucae and other ailments.

Since its flotation in 2001, Henderson has put in a mostly lamentable share price performance, bottoming at 0.43p last August. One bold and loyal backer put in another £250,000 at 0.5p last year and has now been rewarded, at least on paper, with today's 54 per cent rally to 1.24p.

Current prospects hinge on the outcome of the present talks and details of any deal that might possibly emerge.

Robert Tyerman

Related Articles:
ReGen product in US launch	17/10/2007
People who read this article also read ...
Robert Tyerman’s Exploration Insights	11/07/2006
Prospects widen for Zambezi	17/03/2006
Profits surge at Crosby	16/03/2006
New uranium play for AIM	16/03/2006
Latchways	16/03/2006

Add to company folder | Email a friend | Print

Henderson Morley	AIM	£2.42m	0.42p	0.00p
Click here for interactive charting
Other company articles:
Carp deal cheers Henderson			22/05/2008
Herpes group for sale			29/01/2008
Herpes group fishes for funds			02/02/2007
Licensing talks lift Henderson Morley			12/01/2007
GCI grabs research gong			06/11/2006

Sponsored Listings

Savings & Investments Savings & investment options: your official guide.

Compare Over 1100 UK Saving Accounts Arrow1066 provides a savings tool and guide to compare over 1100 UK bank, building society & online savings accounts. Compare interest rates & see how much extra you could earn.